KDR and neoplasm: Furthermore, advancements in nanotechnology are addressing drug delivery challenges; pH-sensitive carriers for VEGFR inhibitors can enhance tumor drug concentration fivefold while concurrently reducing cardiotoxicity by 40% (22).